Sagimet Biosciences Inc.
SGMT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.59 | -0.33 | -0.46 | -0.13 |
| FCF Yield | -30.08% | -24.10% | -6.92% | -6.14% |
| EV / EBITDA | -1.43 | -0.77 | -11.65 | -12.23 |
| Quality | ||||
| ROIC | -34.92% | -33.71% | -110.84% | -41.73% |
| Gross Margin | 0.00% | 100.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.93 | 0.85 | 0.80 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -78.55% | 2.96% | -12.81% | -108.43% |
| Safety | ||||
| Net Debt / EBITDA | 1.66 | 2.44 | -0.00 | 2.32 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -3,158.65 | -2,072.87 |